Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 3/2015

01-03-2015 | Article

Escherichia coli antibiotic resistance in emergency departments. Do local resistance rates matter?

Authors: O. Grignon, E. Montassier, S. Corvec, D. Lepelletier, J.-B. Hardouin, J. Caillon, E. Batard, EDBAC Study Group

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 3/2015

Login to get access

Abstract

Ciprofloxacin and cotrimoxazole are recommended to treat uncomplicated pyelonephritis and uncomplicated cystitis, respectively, provided that local resistance rates of uropathogens do not exceed specified thresholds (10 and 20 %, respectively). However, Escherichia coli resistance rates in Emergency Departments (ED) remain poorly described. Our objectives were to assess E. coli ciprofloxacin and cotrimoxazole resistance rates in EDs of a French administrative region, and to determine if resistance rates differ between EDs. This was a retrospective study of E. coli urine isolates sampled in ten EDs between 2007 and 2012. The following risk factors for resistance were tested using logistic regression: ED, sex, age, sampling year, sampling month. A total of 17,527 isolates were included. Ciprofloxacin local resistance rates (range, 5.3 % [95 % CI, 4.0–7.1 %] to 11.7 % [95 % CI, 5.2–23.2 %]) were ≤10 % in nine EDs in 2012. Five EDs were risk factors for ciprofloxacin resistance, as were male sex, age and sampling in April or October. Cotrimoxazole local resistance rates (range, 13.3 % [95 % CI, 6.3–25.1 %] to 20.4 % [95 % CI, 18.9–22.0 %]) were ≤20 % in seven EDs in 2012. Five EDs were risk factors for cotrimoxazole resistance, as were age, sampling between October and December, and sampling in 2011 and 2012. We found a significant variability of E. coli ciprofloxacin and cotrimoxazole resistance rates among EDs of a small region. These differences impact on the feasibility of empirical treatment of urinary tract infections with ciprofloxacin or cotrimoxazole in a given ED. Continuous local survey of antibacterial resistance in ED urinary isolates is warranted to guide antibacterial therapy of urinary tract infections.
Appendix
Available only for authorised users
Literature
1.
go back to reference Caterino JM, Ting SA, Sisbarro SG et al (2012) Age, nursing home residence, and presentation of urinary tract infection in U.S. emergency departments, 2001–2008. Acad Emerg Med 19:1173–1180CrossRefPubMed Caterino JM, Ting SA, Sisbarro SG et al (2012) Age, nursing home residence, and presentation of urinary tract infection in U.S. emergency departments, 2001–2008. Acad Emerg Med 19:1173–1180CrossRefPubMed
2.
go back to reference Elkharrat D, Brun-Ney D, Cordier B et al (2003) Prescriptions d’antibiotiques dans 34 services d’accueil et de traitement des urgences français Antimicrobial drugs prescribing in 34 french emergency department. Med Mal Infect 33:70–77CrossRef Elkharrat D, Brun-Ney D, Cordier B et al (2003) Prescriptions d’antibiotiques dans 34 services d’accueil et de traitement des urgences français Antimicrobial drugs prescribing in 34 french emergency department. Med Mal Infect 33:70–77CrossRef
3.
go back to reference Gupta K, Hooton TM, Naber KG et al (2011) International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52:e103–e120CrossRefPubMed Gupta K, Hooton TM, Naber KG et al (2011) International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52:e103–e120CrossRefPubMed
4.
go back to reference Lemort ML, Neuville S, Medus M et al (2006) Comparative susceptibility evolution in Escherichia coli from urinary tract infections in outpatients and inpatients at Perpignan hospital in 2002 and 2004. Pathol Biol (Paris) 54:427–430CrossRef Lemort ML, Neuville S, Medus M et al (2006) Comparative susceptibility evolution in Escherichia coli from urinary tract infections in outpatients and inpatients at Perpignan hospital in 2002 and 2004. Pathol Biol (Paris) 54:427–430CrossRef
5.
go back to reference Moffett SE, Frazee BW, Stein JC et al (2012) Antimicrobial resistance in uncomplicated urinary tract infections in 3 California EDs. Am J Emerg Med 30:942–949CrossRefPubMed Moffett SE, Frazee BW, Stein JC et al (2012) Antimicrobial resistance in uncomplicated urinary tract infections in 3 California EDs. Am J Emerg Med 30:942–949CrossRefPubMed
6.
go back to reference Khawcharoenporn T, Vasoo S, Ward E et al (2012) High rates of quinolone resistance among urinary tract infections in the ED. Am J Emerg Med 30:68–74CrossRefPubMed Khawcharoenporn T, Vasoo S, Ward E et al (2012) High rates of quinolone resistance among urinary tract infections in the ED. Am J Emerg Med 30:68–74CrossRefPubMed
7.
go back to reference Filiatrault L, McKay RM, Patrick DM et al (2012) Antibiotic resistance in isolates recovered from women with community-acquired urinary tract infections presenting to a tertiary care emergency department. Can J Emerg Med 14:295–305 Filiatrault L, McKay RM, Patrick DM et al (2012) Antibiotic resistance in isolates recovered from women with community-acquired urinary tract infections presenting to a tertiary care emergency department. Can J Emerg Med 14:295–305
8.
go back to reference Talan DA, Krishnadasan A, Abrahamian FM et al (2008) Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis. Clin Infect Dis 47:1150–1158CrossRefPubMed Talan DA, Krishnadasan A, Abrahamian FM et al (2008) Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis. Clin Infect Dis 47:1150–1158CrossRefPubMed
9.
go back to reference Sun L, Klein EY, Laxminarayan R (2012) Seasonality and temporal correlation between community antibiotic use and resistance in the United States. Clin Infect Dis 55:687–694CrossRefPubMed Sun L, Klein EY, Laxminarayan R (2012) Seasonality and temporal correlation between community antibiotic use and resistance in the United States. Clin Infect Dis 55:687–694CrossRefPubMed
10.
go back to reference Mahamat A, Lavigne JP, Fabbro-Peray P et al (2005) Evolution of fluoroquinolone resistance among Escherichia coli urinary tract isolates from a French university hospital: application of the dynamic regression model. Clin Microbiol Infect 11:301–306CrossRefPubMed Mahamat A, Lavigne JP, Fabbro-Peray P et al (2005) Evolution of fluoroquinolone resistance among Escherichia coli urinary tract isolates from a French university hospital: application of the dynamic regression model. Clin Microbiol Infect 11:301–306CrossRefPubMed
11.
go back to reference Vernaz N, Huttner B, Muscionico D et al (2011) Modelling the impact of antibiotic use on antibiotic-resistant Escherichia coli using population-based data from a large hospital and its surrounding community. J Antimicrob Chemother 66:928–935CrossRefPubMed Vernaz N, Huttner B, Muscionico D et al (2011) Modelling the impact of antibiotic use on antibiotic-resistant Escherichia coli using population-based data from a large hospital and its surrounding community. J Antimicrob Chemother 66:928–935CrossRefPubMed
12.
go back to reference Gallini A, Degris E, Desplas M et al (2010) Influence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant Escherichia coli in a university hospital. J Antimicrob Chemother 65:2650–2657CrossRefPubMed Gallini A, Degris E, Desplas M et al (2010) Influence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant Escherichia coli in a university hospital. J Antimicrob Chemother 65:2650–2657CrossRefPubMed
13.
go back to reference Thibaut S, Caillon J, Huart C et al (2010) Susceptibility to the main antibiotics of Escherichia coli and Staphylococcus aureus strains identified in community acquired infections in France (MedQual, 2004–2007). Med Mal Infect 40:74–80CrossRefPubMed Thibaut S, Caillon J, Huart C et al (2010) Susceptibility to the main antibiotics of Escherichia coli and Staphylococcus aureus strains identified in community acquired infections in France (MedQual, 2004–2007). Med Mal Infect 40:74–80CrossRefPubMed
14.
go back to reference Aldeyab MA, Harbarth S, Vernaz N et al (2012) The impact of antibiotic use on the incidence and resistance pattern of extended-spectrum beta-lactamase-producing bacteria in primary and secondary healthcare settings. Br J Clin Pharmacol 74:171–179CrossRefPubMedCentralPubMed Aldeyab MA, Harbarth S, Vernaz N et al (2012) The impact of antibiotic use on the incidence and resistance pattern of extended-spectrum beta-lactamase-producing bacteria in primary and secondary healthcare settings. Br J Clin Pharmacol 74:171–179CrossRefPubMedCentralPubMed
15.
go back to reference Gottesman BS, Carmeli Y, Shitrit P et al (2009) Impact of quinolone restriction on resistance patterns of Escherichia coli isolated from urine by culture in a community setting. Clin Infect Dis 49:869–875CrossRefPubMed Gottesman BS, Carmeli Y, Shitrit P et al (2009) Impact of quinolone restriction on resistance patterns of Escherichia coli isolated from urine by culture in a community setting. Clin Infect Dis 49:869–875CrossRefPubMed
16.
go back to reference Willemsen I, Cooper B, van Buitenen C et al (2010) Improving quinolone use in hospitals by using a bundle of interventions in an interrupted time series analysis. Antimicrob Agents Chemother 54:3763–3769CrossRefPubMedCentralPubMed Willemsen I, Cooper B, van Buitenen C et al (2010) Improving quinolone use in hospitals by using a bundle of interventions in an interrupted time series analysis. Antimicrob Agents Chemother 54:3763–3769CrossRefPubMedCentralPubMed
17.
go back to reference Slekovec C, Leroy J, Huttner A et al (2014) When the precautionary principle disrupts 3 years of antibiotic stewardship: nitrofurantoin in the treatment of urinary tract infections. J Antimicrob Chemother 69:282–284CrossRefPubMed Slekovec C, Leroy J, Huttner A et al (2014) When the precautionary principle disrupts 3 years of antibiotic stewardship: nitrofurantoin in the treatment of urinary tract infections. J Antimicrob Chemother 69:282–284CrossRefPubMed
18.
go back to reference Batard E, Ollivier F, Boutoille D et al (2013) Relationship between hospital antibiotic use and quinolone resistance in Escherichia coli. Int J Infect Dis 17:e254–e258CrossRefPubMed Batard E, Ollivier F, Boutoille D et al (2013) Relationship between hospital antibiotic use and quinolone resistance in Escherichia coli. Int J Infect Dis 17:e254–e258CrossRefPubMed
19.
go back to reference Kiffer CR, Camargo EC, Shimakura SE et al (2011) A spatial approach for the epidemiology of antibiotic use and resistance in community-based studies: the emergence of urban clusters of Escherichia coli quinolone resistance in Sao Paulo, Brasil. Int J Health Geogr 10:17CrossRefPubMedCentralPubMed Kiffer CR, Camargo EC, Shimakura SE et al (2011) A spatial approach for the epidemiology of antibiotic use and resistance in community-based studies: the emergence of urban clusters of Escherichia coli quinolone resistance in Sao Paulo, Brasil. Int J Health Geogr 10:17CrossRefPubMedCentralPubMed
Metadata
Title
Escherichia coli antibiotic resistance in emergency departments. Do local resistance rates matter?
Authors
O. Grignon
E. Montassier
S. Corvec
D. Lepelletier
J.-B. Hardouin
J. Caillon
E. Batard
EDBAC Study Group
Publication date
01-03-2015
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 3/2015
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-014-2264-y

Other articles of this Issue 3/2015

European Journal of Clinical Microbiology & Infectious Diseases 3/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.